It doesn't matter if you're a growth, value, income, or momentum-focused investor -- building a successful investment portfolio takes skill, research, and a little bit of luck. But what's the best way ...

Phibro (PAHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Let's look at five pharma and drug companies, MRK PFE, LLY, AMGN and BMY, which are scheduled to release their fourth-quarter ...

Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

The Zacks Rank is a unique, proprietary stock-rating model that utilizes earnings estimate revisions to help investors build a winning portfolio. There are four main factors behind the Zacks Rank ...

ATO's first-quarter fiscal 2025 earnings are expected to have continued to benefit from strategic investments and customer ...

The Zacks Consensus Estimate for earnings is pegged at 11 cents, implying 37.5% growth from the year-ago reported quarter.

The Zacks Rank is a unique, proprietary stock-rating model that utilizes earnings estimate revisions to help investors build a winning portfolio. There are four main factors behind the Zacks Rank ...

Nike (NKE) concluded the recent trading session at $76.90, signifying a -1.83% move from its prior day's close.